Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Treating neurodegenerative diseases with cell transplantation has been within reach since
the first pioneering clinical trials in which dopamine neuron progenitors from the fetal brain …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Clinical studies of Parkinson's disease (PD) using a dopamine cell replacment strategy have
been tried for more than 30 years. The outcomes following transplantation of human fetal …

Importance Recent advances in stem cell technologies have rekindled an interest in the use
of cell replacement strategies for patients with Parkinson disease. This study reports the very …

Previous open-label clinical trials have provided proof of principle that intrastriatal
transplants of fetal dopaminergic neurons can induce substantial and long-lasting functional …

Recent news of an impending clinical cell transplantation trial in Parkinson's disease using
parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient …

During the past 40 years brain tissue grafting techniques have been used both to study
fundamental neurobiological questions and to treat neurological diseases. Motor symptoms …

The concept of replacing lost dopamine neurons in Parkinson's disease using
mesencephalic brain cells from fetal cadavers has been supported by over 20 years of …